Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | ACACB | O00763 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | IMPDH2 | P12268 | 3/20 | 0.30 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.30 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.30 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31059149 | 0.82 | HRH3 (0.31) | ACACBHRH3GPR119IMPDH2 | |
| SCHEMBL23317064 | 0.82 | HRH3 (0.31) | ACACBHRH3GPR119IMPDH2 | |
| SCHEMBL31059165 | 0.80 | NAMPT (0.37) | HRH3GPR119IDO1 | |
| SCHEMBL23317404 | 0.80 | NAMPT (0.37) | HRH3GPR119IDO1 | |
| SCHEMBL31059155 | 0.80 | ACACB (0.34) | ACACBHRH3GPR119IMPDH2 | |
| SCHEMBL31059139 | 0.80 | ACACB (0.35) | ACACBHRH3GPR119IMPDH2 | |
| SCHEMBL23317472 | 0.80 | ACACB (0.35) | ACACBHRH3GPR119IMPDH2 | |
| SCHEMBL23317063 | 0.80 | ACACB (0.34) | ACACBHRH3GPR119IMPDH2 | |
| SCHEMBL23317062 | 0.79 | ACACB (0.33) | ACACBHRH3GPR119 | |
| SCHEMBL31059151 | 0.79 | ACACB (0.33) | ACACBHRH3GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230060003-A1 | SPIROCYCLIC O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS | BIOGEN MA INC. | 2023-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230060003-A1 | SPIROCYCLIC O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS | MAN2A1, MAN2B2, ST6GAL1 | KDM4E 4605/4885MAPT 4536/4885THRB 2085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.